In case you missed it

April 19, 2014

Web Version  |  Share with a colleague  |  eNews Subscribe

You are subscribed to the FormularyWatch eNews

In case you missed it
In case you missed it
FormularyWatch

Payers seek new strategies in coordinating costs, management of specialty drugs

As specialty drugs become the standard of care for many complex diseases, they present unique challenges to payers, according to the 10th edition of the EMD Serono Specialty Digest. Specialty drugs can be delivered through various routes of administration (subcutaneous injection, intravenous, intramuscular injection, oral), all of which may have unique coverage criteria, patient cost share, clinical management, and patient access. Read more

Ledipasvir-sofosbuvir combination achieves 90% cure rate for HCV patients without cirrhosis

An 8-week regimen of ledipasvir-sofosbuvir was highly effective (>90% cure) in non-cirrhotic HCV patients with genotype infection, and adding ribavirin or extending treatment to 12 weeks did not significantly improve the results, according to a study published in the New England Journal of Medicine. Read more

In case you missed it

#icymiTwitter Facebook

In case you missed it
Powered by Modern Medicine Advanstar Medical Communications Group